Titre:
  • Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Auteur:Hoskins, P; Vergote, Ignace; Cervantes, Andrés; Tu, Dongsheng; Stuart, G; Zola, Paolo; Poveda, Andrés; Provencher, D; Katsaros, D; Ojeda, B; Ghatage, P; Grimshaw, Rachel; Casado, M.; Elit, L; Mendiola, César; Sugimoto, A; D'Hondt, Veronique; Ozaita, Andrés; Germa, J R; Roy, M; Brotto, L; Chen, Dan; Eisenhauer, Elizabeth
Informations sur la publication:Journal of the National Cancer Institute, 102, 20, page (1547-1556)
Statut de publication:Publié, 2010-10
Sujet CREF:Cancérologie
MeSH keywords:Adult
Aged
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Carboplatin -- administration & dosage
Carcinoma -- drug therapy -- secondary
Cisplatin -- administration & dosage -- adverse effects
Disease-Free Survival
Drug Administration Schedule
Drug Resistance, Neoplasm
Female
Humans
Middle Aged
Neoplasm Staging
Odds Ratio
Ovarian Neoplasms -- drug therapy -- pathology
Paclitaxel -- administration & dosage
Topotecan -- administration & dosage -- adverse effects
Treatment Failure
Note générale:Clinical Trial, Phase III
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0027-8874
info:doi/10.1093/jnci/djq362
info:pii/djq362
info:scp/77958520845
info:pmid/20937992